Friendly bacteria in a nasal spray might tame Kids' allergies
NCT ID NCT03449836
First seen Sep 01, 2026 · Last updated Sep 02, 2026 · Updated 1 time
Summary
This trial tests whether a nasal spray containing two probiotic bacteria strains can reduce allergy symptoms in children aged 6 to 12 with allergic rhinoconjunctivitis, a condition that causes sneezing, a runny nose, and itchy eyes. Researchers will compare the probiotic spray against a standard steroid nasal spray and a placebo. They will measure symptom scores and sleep quality to see if the probiotic offers a safe, non-drug option for managing allergies.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- A nasal spray containing two probiotic bacteria strains (Streptococcus salivarius 24SMBc and Streptococcus oralis 89a)
- What this could lead to
- If it works, this could offer a new, drug-free way to manage allergy symptoms in children and improve their sleep and daily life.
- What could go wrong
- This is a small trial, and the probiotic may not outperform standard treatments or placebo. The study also measures symptoms and sleep quality, which can vary widely.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
60 people
The number who actually took part.
- Started
-
Mar 2018
- Finished
-
Dec 2018
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
6 to 12 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * children aged 6-12 months with allergic rhinoconjunctivitis Exclusion Criteria: * concomitant presence of chronic pathologies, * malformations of the respiratory tract and facial cranium, * tumors, * neurological diseases, * metabolic pathologies, * cystic fibrosis, * immunodeficiencies, * history of epistaxis, * alteration of coagulation factors, * history of apnea, * ciliary dyskinesia, * treatment with topical drugs nasal steroids and / or oral anti-histaminics or antibiotic treatment in the 3 months prior to enrollment.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Allergy are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Naples Federico II
Naples, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Allergy tablets under the tongue may cut hay fever drug use for years, massive real-world study suggests
- Eye insert could ease allergy symptoms for contact lens wearers
- Mystery autumn allergies traced to birch rust?
- AI tool aims to cut allergy misdiagnosis in primary care
- Fish oil for pregnant moms may shield babies from asthma
- Modified pork could revolutionize Alpha-Gal allergy testing